Former rugby stars facing dementia have been given hope for the future, thanks to the inspiring revelations of ex-Wales star Alix Popham. After being diagnosed with early onset dementia and probable chronic traumatic encephalopathy (CTE) in April 2020, Popham underwent experimental brain treatment in Mexico, and the results have been truly life-changing.
Popham, who estimated that his brain had suffered up to 100,000 sub-concussions during his 13-year professional rugby career, is the first former professional sportsman to undergo this pioneering treatment. The treatment, conducted by American biotech firm Neurocytonix, is designed to stimulate brain regeneration and restore the structure of the nervous system for incurable neurological disorders.
Following his treatment, Popham reported significant improvements in his condition: “Things are a lot better. I don’t lose my train of thought anywhere near as much,” he said. “I could feel positive signs after day three…It (the Mexico treatment) was a very positive step forward for me. There are so many ex-players who are struggling, suicidal and depressed and we have got to give them hope.”
Even though the treatment is still pending regulatory approval in the UK and clinical trials are necessary to validate its efficacy, Popham’s experiences offer a glimmer of hope for other former sports stars facing similar health challenges. However, Popham and his wife Mel are determined to fund a UK clinical trial for the treatment through the charity they launched together, Head for Change, to help other individuals in need of such groundbreaking support.
In addition to his own journey, Popham highlighted the positive progress of other rugby players who have received the treatment, as well as the case of football pundit Chris Kamara, who sought treatment at Neurocytonix after experiencing a speech disorder. These success stories serve as an indication of the potential impact of this innovative treatment in transforming the lives of individuals affected by neurodegenerative conditions.
As Popham and his wife continue their efforts to raise funds for the clinical trial, the potential widespread impact of this treatment gives hope not only to current and former athletes but to anyone suffering from neurological diseases. Through their dedication and determination, the Pophams are paving the way for a future where individuals with dementia and neurological disorders can find the help and support they need to lead better lives.
The journey of Alix Popham is a beacon of hope, demonstrating the power of perseverance, innovation, and the unwavering commitment to making a difference in the lives of those affected by these challenging conditions. With continued support and progress, the groundbreaking treatment that has brought hope to Popham and others could become a game-changer in the field of neurodegenerative disease treatment.